Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
07 févr. 2024 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy,...
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
24 janv. 2024 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic...
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
08 janv. 2024 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit Altamira’s two flagship programs, AM-401 and AM-411,...
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
29 déc. 2023 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing...
Altamira Therapeutics Provides Investor and Business Update
11 déc. 2023 08h00 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ETPartial spin-off of Bentrio® business first step in transition to...
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
05 déc. 2023 12h54 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing...
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
29 nov. 2023 10h20 HE
|
Altamira Therapeutics Ltd
- Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29,...
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
17 nov. 2023 09h04 HE
|
Altamira Therapeutics Ltd
Initiates Strategic Repositioning to Focus on Company’s Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue ...
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
10 nov. 2023 08h47 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing...
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
14 sept. 2023 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio® nasal spray in...